v3.25.4
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS      
Cash $ 1,948,271 $ 3,633  
Prepaid expenses and other 419,421 144,356  
Inventory 35,437  
Total current assets 2,403,129 147,989  
TOTAL ASSETS 2,403,129 147,989  
CURRENT LIABILITIES      
Accounts payable 1,060,889 310,219  
Accrued expenses 266,930  
Other current liabilities 111,026  
Derivative liability 3,554,265  
Subscription agreement loan 1,500,000  
Convertible note 4,739,965  
Total current liabilities 13,860,506 1,688,077  
Forward purchase agreement liability 9,901 0  
TOTAL LIABILITIES 13,870,407 1,688,077  
COMMITMENTS AND CONTINGENCIES  
SHAREHOLDERS’ DEFICIT      
Preferred stock, value  
Common stock, value 4,953 2,760  
Additional paid-in capital 11,078,116 1,234,385  
Accumulated deficit (22,550,347) (2,777,233)  
TOTAL SHAREHOLDERS’ DEFICIT (11,467,278) (1,540,088) $ (487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT 2,403,129 147,989  
Affiliates [Member]      
CURRENT LIABILITIES      
Other current liabilities 353,679  
Related Party [Member]      
CURRENT LIABILITIES      
Notes payable - related party 885,564 1,266,832  
Promissory note fee - related party 1,000,000  
Loan and transfer notes payable - related party $ 499,214  
Aspire Biopharma Inc [Member]      
CURRENT ASSETS      
Cash   3,633 11,174
Prepaid expenses and other   144,356 35,000
Subscriptions Receivable  
Total current assets   147,989 46,174
TOTAL ASSETS   147,989 46,174
CURRENT LIABILITIES      
Accounts payable   310,219 172,773
Loan and transfer notes payable - related party   1,266,832 360,636
Other current liabilities   111,026 626
Total current liabilities   1,688,077 534,035
TOTAL LIABILITIES   1,688,077 534,035
COMMITMENTS AND CONTINGENCIES    
SHAREHOLDERS’ DEFICIT      
Common stock, value   22,000 22,000
Additional paid-in capital   1,215,113 957,500
Accumulated deficit   (2,777,233) (1,467,361)
TOTAL SHAREHOLDERS’ DEFICIT   (1,540,088) (487,861)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT   147,989 46,174
Aspire Biopharma Inc [Member] | Series A Preferred Stock [Member]      
SHAREHOLDERS’ DEFICIT      
Preferred stock, value   $ 32